LLY

768.85

+0.75%↑

JNJ

176.51

-0.72%↓

ABBV

220.71

+0.68%↑

UNH

341.39

-0.06%↓

AZN

76.89

-1.07%↓

LLY

768.85

+0.75%↑

JNJ

176.51

-0.72%↓

ABBV

220.71

+0.68%↑

UNH

341.39

-0.06%↓

AZN

76.89

-1.07%↓

LLY

768.85

+0.75%↑

JNJ

176.51

-0.72%↓

ABBV

220.71

+0.68%↑

UNH

341.39

-0.06%↓

AZN

76.89

-1.07%↓

LLY

768.85

+0.75%↑

JNJ

176.51

-0.72%↓

ABBV

220.71

+0.68%↑

UNH

341.39

-0.06%↓

AZN

76.89

-1.07%↓

LLY

768.85

+0.75%↑

JNJ

176.51

-0.72%↓

ABBV

220.71

+0.68%↑

UNH

341.39

-0.06%↓

AZN

76.89

-1.07%↓

Search

Harmony Biosciences Holdings Inc

Slēgts

SektorsVeselības aprūpe

31.88 -1.09

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

31.88

Max

32.74

Galvenie mērījumi

By Trading Economics

Ienākumi

-5.8M

40M

Pārdošana

16M

200M

P/E

Sektora vidējais

10.45

35.293

EPS

0.92

Peļņas marža

19.839

Darbinieki

268

EBITDA

3M

59M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+56.03% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 28. okt.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-171M

1.9B

Iepriekšējā atvēršanas cena

32.97

Iepriekšējā slēgšanas cena

31.88

Ziņu noskaņojums

By Acuity

20%

80%

37 / 371 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bullish Evidence

Harmony Biosciences Holdings Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 17. sept. 23:01 UTC

Iegādes, apvienošanās, pārņemšana

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid -- Update

2025. g. 17. sept. 22:48 UTC

Iegādes, apvienošanās, pārņemšana

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid

2025. g. 17. sept. 21:59 UTC

Peļņas

Cryptocurrency-Exchange Bullish Swings to Profit in First Report as Public Company

2025. g. 17. sept. 23:44 UTC

Tirgus saruna

Nikkei May Rise as Yen Weakens -- Market Talk

2025. g. 17. sept. 23:39 UTC

Tirgus saruna

Gold Rises Amid Prospects of Further Fed Rate Cuts -- Market Talk

2025. g. 17. sept. 22:20 UTC

Iegādes, apvienošanās, pārņemšana

Santos: XRG Consortium Wouldn't Agree to Appropriate Risk Allocation Between It and Santos Shareholders

2025. g. 17. sept. 22:20 UTC

Iegādes, apvienošanās, pārņemšana

Santos: XRG Consortium Wouldn't Agree to Acceptable Terms That Protected Value of Transaction

2025. g. 17. sept. 22:20 UTC

Iegādes, apvienošanās, pārņemšana

Santos Had Expressed Concern to XRG Consortium About Delays in Agreeing to Scheme Implementation Agreement

2025. g. 17. sept. 22:19 UTC

Iegādes, apvienošanās, pārņemšana

Santos: Consortium Notified Board of Decision to Withdraw Proposal on Weds Evening

2025. g. 17. sept. 22:18 UTC

Iegādes, apvienošanās, pārņemšana

Santos Confirms XRG Consortium Has Withdrawn Takeover Proposal

2025. g. 17. sept. 21:00 UTC

Peļņas

Darden Restaurants to Report Earnings. Why the Olive Garden Parent Is Expected to Stay Strong. -- Barrons.com

2025. g. 17. sept. 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2025. g. 17. sept. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 17. sept. 19:59 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 17. sept. 19:59 UTC

Tirgus saruna

Treasury Yields, Dollar Rise as Fed Cuts, Powell Warns of Risks -- Market Talk

2025. g. 17. sept. 19:07 UTC

Tirgus saruna

Oil Futures Snap Three-Session Winning Streak -- Market Talk

2025. g. 17. sept. 18:43 UTC

Tirgus saruna

Treasury Yields, Dollar Reverse Course as Powell Talks to Reporters -- Market Talk

2025. g. 17. sept. 18:38 UTC

Tirgus saruna

U.S. Natural Gas Futures Mixed Ahead of Storage Data -- Market Talk

2025. g. 17. sept. 18:20 UTC

Tirgus saruna

Gold Dips After Quarter-Point Rate Cut -- Market Talk

2025. g. 17. sept. 18:18 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 17. sept. 18:18 UTC

Tirgus saruna

Treasury Yields, Dollar Fall on Nearly Unanimous Fed Cut -- Market Talk

2025. g. 17. sept. 18:14 UTC

Tirgus saruna

Oil Slips Some More as Fed Makes Expected 25 Bp Rate Cut -- Market Talk

2025. g. 17. sept. 17:59 UTC

Tirgus saruna

Soyoil Takes Hit as Traders Consider EPA Proposal -- Market Talk

2025. g. 17. sept. 17:15 UTC

Iegādes, apvienošanās, pārņemšana

Netflix 'Has Won The Streaming Wars,' Analyst Says. The Stock Is a Buy. -- Barrons.com

2025. g. 17. sept. 17:06 UTC

Iegādes, apvienošanās, pārņemšana

Walmart Stock Heads for a Record High. The Retailer Could Become a Leader in 'Agentic' AI. -- Barrons.com

2025. g. 17. sept. 16:51 UTC

Peļņas

Correct: Exor 1H Net Loss -EUR624M

2025. g. 17. sept. 16:34 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 17. sept. 16:34 UTC

Tirgus saruna

Bank of Canada Ditches Resilience Talk, Plays Up Slowing Growth -- Market Talk

2025. g. 17. sept. 16:25 UTC

Peļņas

Wolters Kluwer: July, August Saw a Slight Increase in Organic Growth Compared to 1H

2025. g. 17. sept. 16:23 UTC

Peļņas

Wolters Kluwer: Year-to-Date Performance In Line With 2025 Guidance

Salīdzinājums

Cenas izmaiņa

Harmony Biosciences Holdings Inc Prognoze

Cenas mērķis

By TipRanks

56.03% augšup

Prognoze 12 mēnešiem

Vidējais 50.71 USD  56.03%

Augstākais 70 USD

Zemākais 33 USD

Pamatojoties uz 8 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Harmony Biosciences Holdings Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

8 ratings

7

Pirkt

1

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

29.8 / N/AAtbalsts un pretestība

Īstermiņā

Weak Bullish Evidence

Vidējā termiņā

Weak Bullish Evidence

Ilgtermiņā

Very Strong Bearish Evidence

Noskaņojums

By Acuity

37 / 371 Rangs Veselības aprūpe

Ziņu noskaņojums

Ļoti spēcīga liecība "buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
help-icon Live chat